

CERTIFICATE OF ANALYSIS

* FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.

NIGERIAN SILK KUSH LIVE RESIN BHO (CONCENTRATE) // PRODUCED: JAN 17, 2022

CLIENT: THIRD SHIFT RESIN // BATCH: PASS



MATRIX: CONCENTRATE
SAMPLE ID: NAL-220112-019
COLLECTED ON: JAN 12, 2022
RECEIVED ON: JAN 12, 2022
SAMPLE SIZE: 1.0 G

RECEIVED BY: MIC LABEL

CANNABINOID OVERVIEW

THCA:	77.7 %
CBGA:	6.40 %
TOTAL CANNABINOIDS:	85.4 %

BATCH RESULT: PASS

POTENCY	TESTED
SOLVENTS	PASS
TERPENES	TESTED

CAN. 1: POTENCY & CANNABINOID PROFILE BY HPLC-UV PREPARATION: JAN 13, 2022 // ANALYSIS: JAN 14, 2022

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
CBC		ND	ND	0.142/0.709	N/A
CBCA		ND	ND	0.142/0.709	N/A
CBD		ND	ND	0.142/0.709	N/A
CBDA		ND	ND	0.142/0.709	N/A
CBDV		ND	ND	0.142/0.709	N/A
CBDVA		ND	ND	0.142/0.709	N/A
CBG		ND	ND	0.142/0.709	N/A
CBGA	6.40 %	64.0 mg/g	64.0 mg/g	0.142/0.709	N/A
CBL		ND	ND	0.142/0.709	N/A
CBLA		ND	ND	0.142/0.709	N/A
CBN		ND	ND	0.142/0.709	N/A

ANALYTE	LIMIT	AMT	AMT	LOD/LOQ (%)	PASS/FAIL
CBNA		ND	ND	0.142/0.709	N/A
Δ ⁸ -THC		ND	ND	0.142/0.709	N/A
Δ ⁹ -THC		1.26 %	12.6 mg/g	0.142/0.709	N/A
Δ ¹⁰ -THC		ND	ND	0.142/0.709	N/A
EXO-THC		ND	ND	0.142/0.709	N/A
THCA	77.7 %	777 mg/g	777 mg/g	0.142/0.709	N/A
THCV		ND	ND	0.142/0.709	N/A
THCVA	< LOQ	< LOQ	< LOQ	0.142/0.709	N/A
TOTAL THC **		69.4 %	694 mg/g		N/A
TOTAL CBD **		ND	ND		N/A

** TOTAL CBD = (CBDA X 0.877) + CBD

** TOTAL THC = (THCA X 0.877) + THC

Reported on an as received basis

1000 µg/g = 1 mg/g



RESULTS CERTIFIED BY:
BARRY CHAFFIN
COO, NOVA ANALYTIC LABS
JAN 17, 2022

RESULTS CERTIFIED BY:
GREG NEWLAND
CSO, NOVA ANALYTIC LABS
JAN 17, 2022

RESULTS CERTIFIED BY:
CHRIS ALTOMARE
CEO, NOVA ANALYTIC LABS
JAN 17, 2022

TERPENES BY HEADSPACE GC-MS
PREPARATION: JAN 13, 2022 // ANALYSIS: JAN 14, 2022

ANALYTE	AMT	AMT	LOD/LOQ (mg/g)	PASS/FAIL
TOTAL TERPENES	8.71 %	87.1 mg/g		N/A
TERPINOLENE	4.04 %	40.4 mg/g	0.137/0.274	N/A
β-MYRCENE	1.11 %	11.1 mg/g	0.137/0.274	N/A
D-LIMONENE	0.942 %	9.42 mg/g	0.137/0.274	N/A
α-TERPINENE	0.713 %	7.13 mg/g	0.137/0.274	N/A
α-PINENE	0.554 %	5.54 mg/g	0.137/0.274	N/A
Δ ³ -CARENE	0.119 %	1.19 mg/g	0.137/0.274	N/A
α-OCIMENE	0.490 %	4.90 mg/g	0.0684/0.137	N/A
β-PINENE	0.220 %	2.20 mg/g	0.137/0.274	N/A
γ-TERPINENE	0.150 %	1.50 mg/g	0.137/0.274	N/A
β-CARYOPHYLLENE	0.100 %	1.00 mg/g	0.137/0.274	N/A
CAMPHENE	0.0969 %	0.969 mg/g	0.137/0.274	N/A

ANALYTE	AMT	AMT	LOD/LOQ (mg/g)	PASS/FAIL
α-HUMULENE	0.0768 %	0.768 mg/g	0.137/0.274	N/A
LINALOOL	0.0668 %	0.668 mg/g	0.137/0.274	N/A
P-CYMENE	0.0347 %	0.347 mg/g	0.137/0.274	N/A
EUCALYPTOL	< LOQ	< LOQ	0.137/0.274	N/A
α-BISABOLIDOL	ND	ND	0.137/0.274	N/A
CIS-NEROLIDOL	ND	ND	0.137/0.274	N/A
ISOPULEGOL	ND	ND	0.137/0.274	N/A
GERANIOL	ND	ND	0.137/0.274	N/A
CARYOPHYLLENE OXIDE	ND	ND	0.137/0.274	N/A
β-OCIMENE	ND	ND	0.0684/0.137	N/A
TRANS-NEROLIDOL	ND	ND	0.137/0.274	N/A

RSOL.1: RESIDUAL SOLVENTS, POISONS AND TOXINS BY HEADSPACE GC-MS
PREPARATION: JAN 14, 2022 // ANALYSIS: JAN 15, 2022

ANALYTE	LIMIT	AMT (µg/g)	LOD/LOQ (µg/g)	PASS/FAIL
1,2-DICHLOROETHANE	1 µg/g	ND	0.699/1.40	PASS
ACETONE	5000 µg/g	ND	14.0/28.0	PASS
ACETONITRILE	410 µg/g	ND	14.0/28.0	PASS
BENZENE	1 µg/g	ND	0.699/1.40	PASS
BUTANE	5000 µg/g	254	1.40/3.50	PASS
CHLOROFORM	1 µg/g	ND	0.699/1.40	PASS
ETHANOL	5000 µg/g	ND	14.0/28.0	PASS
ETHYL ACETATE	5000 µg/g	ND	14.0/28.0	PASS
ETHYLENE OXIDE	1 µg/g	ND	0.699/1.40	PASS
ETHYL ETHER	5000 µg/g	ND	14.0/28.0	PASS
HEPTANE	5000 µg/g	ND	14.0/28.0	PASS

ANALYTE	LIMIT	AMT (µg/g)	LOD/LOQ (µg/g)	PASS/FAIL
HEXANE	290 µg/g	ND	1.40/3.50	PASS
ISOPROPYL ALCOHOL	5000 µg/g	145	28.0/55.9	PASS
METHANOL	3000 µg/g	ND	14.0/69.9	PASS
METHYLENE CHLORIDE	1 µg/g	ND	0.699/1.40	PASS
PENTANE	5000 µg/g	ND	14.0/28.0	PASS
PROPANE	5000 µg/g	ND	28.0/55.9	PASS
TOLUENE	890 µg/g	ND	6.99/14.0	PASS
TRICHLOROETHYLENE	1 µg/g	ND	0.699/1.40	PASS
O-XYLENE	2170 µg/g	ND	1.40/6.99	PASS
P- AND M-XYLENE	2170 µg/g	ND	2.80/6.99	PASS
TOTAL XYLENES	2170 µg/g	ND		PASS

** FOR QUALITY ASSURANCE PURPOSES. NOT A MAINE COMPLIANCE CERTIFICATE.*

ALL TESTS WERE PERFORMED IN ACCORDANCE WITH THE RULES AND REGULATIONS SET FORTH IN THE MAINE ADULT USE PROGRAM. LABORATORY SAMPLING PROTOCOLS ARE GOVERNED BY THE OMP'S SAMPLING GUIDANCE DOCUMENTS. ALL INFORMATION PROVIDED BY THE CLIENT, INCLUDING SELF SAMPLING, MUST BE ACCURATE AND ADHERE TO THE SAME RULES AND REGULATIONS. HOWEVER, CLIENT PROVIDED INFORMATION, INCLUDING SAMPLING, IS ULTIMATELY THE RESPONSIBILITY OF THE PROVIDING LICENSEE, REGISTERED CAREGIVER, PATIENT OR THE LIKE AND FAILURE TO FOLLOW SAID PROTOCOLS COULD LEAD TO ERRONEOUS TEST RESULTS. NOTE: NOT ALL POTENTIAL AND/OR EXISTING HAZARDS WERE ANALYZED.

END OF REPORT

